ATEMs has expertise in the field of tissue engineering
ATEMs has expertise in the field of
tissue engineering
AMC is a cartilage cell separated from immature cartilage tissue, As a cell source with a similar level of
safety to autologous cells or adult stem cells, it has superior proliferative and differentiation capacity than adult stem cells.
It is a new cell source for tissue regeneration therapy that can be applied to various technologies and product development.
Patent Number: (10-15368150000) : Medicinal composition for the prevention and treatment of
immune diseases using fetal cartilage-derived cells
Patent Number: (10-15836660000): Medicinal composition for the prevention and treatment of
autoimmune diseases or transplant rejection diseases using fetal cartilage-derived cells.
In vivo bioreactor using cellulose membrane benefit engineering cartilage by improving the
chondrogenesis and modulating the immune response. Tissue Engineering and Regenerative Medicine. 2020
Engineered Cartilage Utilizing Fetal Cartilage-Derived Progenitor Cells for Cartilage Repair.
scientific report. 2020
Immunophenotype and Immune-Modulatory Activities of Human Fetal Cartilage-Derived Progenitor Cells.
Cell Transplant. 2019
Characterization of Human Fetal Cartilage Progenitor Cells During Long-Term Expansion in a Xeno-Free Medium.
Tissue Engineering and Regenerative Medicine. 2018
Comparison of fetal cartilage-derived progenitor cells isolated at different developmental stages in a rat model.
Dev Growth Differ. 2016
Fetal Cartilage-derived Cells have Stem Cell Properties and are a Highly Potent Cell Source for Cartilage Regeneration.
Cell Transplant. 2015
AMC is a cartilage cell separated from immature cartilage tissue,
As a cell source with a similar level of safety to autologous cells or adult
stem cells, it has superior proliferative and differentiation capacity than
adult stem cells. It is a new cell source for tissue regeneration therapy
that can be applied to various technologies and product development.
Patent Number: (10-15368150000) : Medicinal
composition for the prevention and treatment of
immune diseases using fetal cartilage-derived cells
Patent Number: (10-15836660000): Medicinal
composition for the prevention and treatment of
autoimmune diseases or transplant rejection diseases
using fetal cartilage-derived cells.
In vivo bioreactor using cellulose membrane benefit
engineering cartilage by improving the
chondrogenesis and modulating the immune response.
Tissue Engineering and Regenerative Medicine. 2020
Engineered Cartilage Utilizing Fetal Cartilage-Derived
Progenitor Cells for Cartilage Repair.
scientific report. 2020
Immunophenotype and Immune-Modulatory Activities
of Human Fetal Cartilage-Derived Progenitor Cells.
Cell Transplant. 2019
Characterization of Human Fetal Cartilage
Progenitor Cells During Long-Term
Expansion in a Xeno-Free Medium.
Tissue Engineering and Regenerative Medicine. 2018
Comparison of fetal cartilage-derived progenitor cells
isolated at different developmental stages in a rat model.
Dev Growth Differ. 2016
Fetal Cartilage-derived Cells have Stem Cell Properties
and are a Highly Potent Cell Source for Cartilage
Regeneration. Cell Transplant. 2015